Annual Report

Overview

The report describes a strong FY2017, with consolidated revenue of ¥353,380 million and continued progress toward global commercialization of burosumab and mogamulizumab. It also details a formal CSR materiality process, including Group CSR Committee approval and monitoring. Environmental priorities include a 20% CO2 emissions reduction target and a 30% water-use reduction target by 2030, both compared with 2015.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2017
Period: 1 January 2017 – 31 December 2017
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services